GPC3 and neoplasm: For CAR-T approaches targeting GPC3, early-phase studies report on-target toxicity risks, including cytokine release syndrome (CRS) and potential on-target, off-tumor effects if low-level GPC3 is expressed in normal tissues; close monitoring and step-up dosing strategies may mitigate these risks [60].